

MicroRNA Discovery[™] Kit

Cat. # RA410A-1

User Manual

Store kit at -20°C on receipt

A limited-use label license covers this product. By use of this product, you accept the terms and conditions outlined in the Licensing and Warranty Statement contained in this user manual.

(ver. 3-061101)

Contents

I.	Intro	oduction and Background	
	A .	Overview	2
	В.	Importance of MicroRNAs and Other Small RNAs	2
	C .	Overview of Protocol	3
	D.	List of Components	6
	E. /	Additional Required Materials	6
	F.	Procedural Guidelines	6
П.	Pro	tocol	
	A. 3	Starting RNA	7
	B . /	Adaptor Ligation	7
	C.	First-Strand cDNA Synthesis	8
	D .	PCR Amplification	8
	Ε. ΄	TOPO TA Cloning	9
	F. 3	Sample Screening Guidelines for Identification of Putative	
	I	miRNA or miRNA-like Molecules in Amplified cDNA	10
	G. 3	Size Selection of Amplified cDNA (optional)	13
	Н. (Gene-Specific Amplification Using Amplified cDNA	14
Ш.	Tro	ubleshooting	
	A.	No Product from cDNA Amplification	16
	B.	No Product with Gene-Specific Primers	16
	C.	No Colonies after TOPO TA cloning	16
	D.	No Product with PCR primer during colony screening1	16
IV.	Ref	erences	18
	-		-
V.	App	pendix	
	A.	Data Generated with the MicroRNA Discovery™ Kit2	20
	B.	Related Products	24
	С.	Technical Support	24
VI.	Lice	ensing and Warranty Statement	25
		· · · · · · · · · · · · · · · · · · ·	

I. Introduction and Background

A. Overview

This manual provides details and information necessary to use the MicroRNA Discovery[™] Kit to uniformly and reproducibly amplify limited amounts of non-degraded as well as degraded RNA to provide sufficient template for the cloning of selected small RNA gene transcripts processed by RNase III. To ensure optimal results, please read the entire manual before using the reagents and material supplied with this kit.

B. Importance of MicroRNAs and Other Small Non-Coding RNAs

The field of non-coding RNAs has gained increasing attention in recent years, particularly due to the discovery of micro RNAs (miRNA). Micro RNAs are short (typically 19-24 nucleotides) single stranded RNAs that regulate the expression of target genes by interacting with complementary sites in the 3' UTR of the target mRNAs and inhibiting translation. miRNAs are a conserved group of non-coding RNAs with very important regulatory roles.

Mature miRNAs are excised from stem-loop precursors, which are themselves transcribed as part of longer primary transcripts. These primary miRNAs appear to be first processed by the RNase Drosha in the nucleus, after which the precursor miRNAs are exported to the cytoplasm where the RNase Dicer further processes them. These enzymes are also involved in the generation of mature small inhibitory RNAs (siRNA) from exogenously transferred double stranded siRNA precursors.

The current method for identifying novel miRNA molecules involves many steps and can take several days to complete. The method of Lagos-Quintana, et al requires three size selection steps of small RNA, two ligation steps—each requiring gel electrophoresis and RNA extraction steps—a reverse transcription step, followed by PCR amplification. SBI's MicroRNA Discovery[™] Kit drastically reduces both the labor and time required to investigate miRNA populations. The kit utilizes an innovative set of degenerate adaptors to specifically recover RNase III processed molecules, including mature miRNAs as well as larger stem loop precursor molecules that current methods miss.

Recently, previously unknown germline specific classes of miRNA-like molecules were identified in mouse testes and mouse oocytes, illustrating the need for continued and in depth miRNA discovery efforts across a wide range of tissues. These facts taken together demonstrate an ever-increasing need for simple, robust, and sensitive methods that enable discovery and quantitation of microRNAs and their precursors.

C. Overview of Protocol





SBI's small RNA amplification system includes 3 steps, which can be completed in less than 4 hours:

- A degenerate adaptor mixture is ligated to both the 5'-end and 3'ends of total RNA. Our use of chimeric DNA/RNA adaptors unique cocktail of enzymes, and optimized reaction conditions ensure efficient ligation. Figure 2 describes this process in detail, and Table 1 contains the sequences for the adaptor.
- 2. Reverse transcription of the RNA using a primer complementary to the attached adaptor.
- 3. PCR amplification of the cDNA.

The amplified cDNA is ready for direct TOPO-TA cloning (Invitrogen, Cat. # K4500-01) with no additional purification necessary. If desired, the amplified cDNA can also be cloned by standard cloning protocols.

```
Upper strand adaptor
1. 5'- P ACTCTGCGTTGATACCACTGCTT-3'
Lower strand adaptors
2. 3'-rNrTrGrAGACGCAACTATGGTGACGAA NH2-5'
3'-rNrNrTrGrAGACGCAACTATGGTGACGAA NH2-5'
4. 3'-rNrNrNrTrGrAGACGCAACTATGGTGACGAA NH2-5'
5. 3'-rNrNrNrTrGrAGACGCAACTATGGTGACGAA NH2-5'
5. 3'-rNrNrNrTrGrAGACGCAACTATGGTGACGAA NH2-5'
6. 5'-AAGCAGTGGTATCAACGCAGAGT-3'
```





Fig. 2. Depiction of degenerate adaptor ligation step. A pool of double-stranded degenerate adaptors, which have a variable 3' overhang, is ligated to total RNA.

The expected size distribution and banding pattern of amplified cDNA is shown in Figure 3 below. The size of the amplified cDNA can be refined through the use of a size selection step (see Part II, step C, and Figure 4 in this manual). While optional, we have found that this step can reduce the number of background clones resulting from ribosomal and transfer RNA transcripts, as well as increase the number of mature miRNAs recovered.



Fig. 3. Size distribution of amplified cDNA from different tissues.

D. List of Components

Each MicroRNA Discovery[™] Kit provides enough material to amplify miRNA-like molecules from 10 different RNA samples (10 reactions).

- 10 μI Ligase Cocktail (T4 DNA & RNA ligase)
- 70 μl Ligation Buffer
- 8 μl Control RNA (500 ng/μl)
- 1.2 ml RNase-free Water
- 10 μl Ligation Adaptor Mix
- 60 μl RT and PCR Primer
- 10 μl Reverse Transcriptase
- 60 μl 5X Reverse Transcriptase Buffer
- 20 μl Dithiothreitol (DTT)
- 50 μ l dNTP Mix (10 μ M each)
- 150 μl 10X PCR Buffer
 - 25 μl PCR Polymerase (50X)

The kits are shipped in blue ice and should be stored at -20°C upon receipt. Properly stored kits are stable for 1 year from the date received.

E. Additional Required Materials

- TOPO TA Cloning Kit (Invitrogen, Cat. # K4500-01)
- Microbiological plates with LB-agar with 50 μg/ml ampicillin
- Thermocycler (with heated lid)
- 3.0-3.5% Agarose Gel in Tris-Borate EDTA (TBE) or Tris-Acetate EDTA (TAE) Buffer
- DNA Size Ladder with markers from 50 to 2,000 bp (Bio-Rad AmpliSize[™] DNA Ladder; Cat. # 170-8200)
- Optional for samples from sources with high RNase activity: Ribonuclease Inhibitor (Ambion SUPERase-IN™; Cat. # AM2694)
- Optional for size-selection of Amplified cDNA: QIAquick Gel Extraction Kit (QIAGEN, Cat. # 28704)

F. Procedural Guidelines

- Before dispensing, completely thaw all reagents and vortex to mix thoroughly.
- Briefly centrifuge each mixture once to ensure there is no solution left on the sides/lid of the tube.
- When setting up multiple reactions, we recommend that you prepare a master mix.

II. Protocol

A. Starting RNA

We recommend starting with approximately 500 ng of total RNA. Our studies have consistently shown greater than 95% representation of RNA species in the amplified population when compared with unamplified RNA with starting concentrations greater than or equal to $500 \text{ ng/}\mu\text{l}$.

IMPORTANT NOTE: *The RNA isolated by the investigator must contain small RNA.* We suggest using RNA isolated using an acid phenol method of extraction, such as TRIzol (Invitrogen, Cat. # 15596-026). We recommend Ambion's mirVana[™] miRNA Isolation Kit (Cat. # AM1560) for the isolation of small RNAs.

B. Adaptor Ligation

1.	For each RNA sample, add the components to a 0.2 or 0.5 ml PCR
	tube in the order specified:

5.0 μl	RNase-free Water
2.0 μl	Ligase buffer (warmed to 37°C before use)
1.0 μl	Ligation Adaptor Mix
1.0 μl	Total RNA
1.0 μl	Ligase Cocktail
10.0 ul	Total volume

Note: Because reagent volumes are small, accurate pipetting is critical.

 Incubate the reactions at 16°C for 1 hour, and then keep on ice until the RT step (Step C). The ligation reactions can be also be stored at -70°C and used later.

C. First-Strand cDNA Synthesis

1. For each RNA sample, add the components to a 0.2 or 0.5 ml PCR tube in the order specified:

6.0	μl	RNase-free Water

- 1.0 μl RT and PCR Primer
- 5.0 μl Ligation (from Step B)

12.0 µl Total volume

- 2. Incubate the reactions at 95°C for 3 minutes, and then allow tubes to cool down to room temperature. Keep reactions on ice until you are ready to start the RT step.
- 3. While the reactions are incubating, set up a Master Mix sufficient for the number of first-strand synthesis reactions you are processing. This is done by adding to a microfuge tube the volume of each of the following components multiplied by the number of reactions you are processing:

4.0 μl	5X Reverse Transcriptase Buffer
2.0 µl	dNTP Mix
1.0 μl	Dithiothreitol (DTT)
1.0 µl	Reverse Transcriptase
8.0 μl	Total volume

Note: If you have 2 reactions, you should have 16 μ l of Master Mix; if you have 3 reactions, 24.0 μ l, etc.

- 4. Add 8.0 μ l of the Master Mix set up in step 3 to the 12 μ l ligation reaction from step 2. Mix well by pipetting up and down.
- 5. Incubate the first-strand reactions for 1 hour at 42°C, and then immediately place them at 95°C for 5 minutes. Keep reactions on ice. The first-strand cDNA can be stored at -20°C until you are ready to proceed with the PCR Amplification.

D. PCR Amplification

1. Use 2 μl of reaction mix from RT reaction for PCR amplification. To each first-strand synthesis reaction from Part C, add the following:

82 μ	RNase-free Water
10 µ	I 10X PCR Buffer
2 μ	l dNTP Mix
2 μ	I RT and PCR Primer
2μ	I PCR Polymerase (50X)
100 μ	I Total volume (including the 2 μl from Part C)

- 2. Place the reactions in a thermal cycler, and cycle using the following program:
 - 95°C for 2 min
 - 95°C for 20 sec
 - 68°C for 25 sec _

30 cycles (Stop at 20 cycles if you decide to perform size selection—see Part E.)

- 68°C for 1 min
- 15°C hold

Note: You will need to vary the number of cycles depending on the amount of starting RNA. Refer to the table below to determine the approximate number of times you should cycle:

Starting <u>RNA</u>	<u># Cycles *</u>
1 μg	27
500 ng	30

The # of cycles depends on the amount of total RNA used in the ligation reaction. *

 After amplification, run 2.5 µl of each reaction on a 3.0-3.5% agarose gel in 1X TBE or TAE Buffer. Include a DNA size ladder with markers in the range of 50-2,000 bp (e.g., Bio-Rad AmpliSize[™] DNA Ladder). You should see results similar to those shown in Figure 5. The typical yield from 500 ng RNA and above is 2-3 µg cDNA; from 50 ng, the yield is 1-1.5 µg.

Depending on your particular RNA sample, more cycles may be necessary. If so, perform an additional 2 cycles and check your amplified cDNA again. You do not need to add additional PCR Polymerase, even if your reaction was cycled overnight, as long as you held the reaction at 15°C after cycling. You can continue adding two-cycle increments until you see the sufficient product from your amplification reaction, however, you should not exceed 40 cycles. The amplified cDNA may be stored at 4°C for a couple of weeks. For long-term storage, we recommend storing the cDNA at -20°C.

E. TOPO TA Cloning

When using Invitrogen's TOPO TA Cloning Kit, follow the manufacturer's protocol. We recommend using 4 μ l of amplified cDNA in a 6 μ l TOPO cloning reaction.

F. Sample Screening Guidelines for Identification of Putative miRNA or miRNA-like Molecules in Amplified cDNA

- 1. After cloning the cDNAs into the TOPO cloning vector (Invitrogen), select white colonies and transfer them to a 96-well flat bottom microtiter plate with 100 μ l LB media supplemented with 100 μ g/ml ampicillin. Grow colonies in the shaker at 37°C for two hours.
- 2. To analyze the size of the inserts, prepare a PCR master mix for the number of reactions equal to number of the clones that need to be analyzed.

	<u>1 Rxn</u>		<u>10 Rx</u>	<u>(n</u>
RNase-free Water	16.0	μl	160	μl
10X PCR Buffer	2.0	μl	20	μl
50X dNTP Mix (10 μM each)	0.4	μl	4	μl
RT and PCR Primer	0.5	μl	5	μl
PCR Polymerase	0.5	μl	6	μl
Total volume	19.4	μl	194	μl

- 3. Aliquot 19.4 µl of PCR master mix to 96-well PCR plate. Transfer 0.6 µl of cell culture directly from the 96-well flat bottom plate to the 96-well PCR plate. Seal the top of the PCR plate and place into the PCR thermal cycler.
- 4. Cycle using the following program:
 - 95°C for 2 min
 - 95°C for 20 sec
 68°C for 25 sec
 25 cycles

 - 15°C hold
- 5. After amplification, analyze 2.5 µl of each reaction on a 3.0-3.5% agarose gel in 1X TBE or TAE Buffer. Include a DNA size ladder with markers in the range of 50-2,000 bp (e.g., Bio-Rad AmpliSize™ DNA Ladder, Cat. # 170-8200).
- Select clones with inserts of desired. 6.

Note: RT-PCR primer will add approximately 50 base pairs (bp) to the size of the insert. *i.e.* clones with insert of 70-85 bp will be more likely contain mature form of miRNA or miRNA-like molecules. Larger inserts may contain precursors of miRNA or miRNA-like molecules.

- 7. Grow cells with desired size insert for plasmid purification followed by sequencing. For sequencing, we recommend purifying plasmid from 3 ml of overnight culture using QIAGEN's QIAprep Spin Miniprep Kit (Cat. # 27104).
- 8. After sequencing, identify flanking vector sequences containing BamHI sites (GGATCC). Trim adaptor sequences from both sides of the insert (24 nucleotides for the adaptor). The remaining internal sequence is the actual insert sequence which requires further analysis.
- 9. Use this sequence for a BLAST search against GenBank (http://www.ncbi.nlm.nih.gov). Choose the database from the appropriate organism for your search to eliminate unrelated hits. For clones from human sources, use the human database; for mouse sources of RNA, use the mouse database, and so on. The first GenBank BLAST search serves to rapidly eliminate background

sequences derived from rRNA and tRNA and their degradation products. When analyzing results from the first BLAST be aware that some mRNA may have extensive homology (up to 180-200 nt) to rRNA and omitting clones containing these inserts may limit the number of potential microRNA sequences for discovery. In parallel, you can BLAST search this sequence against the mRNA database (RefSeq of GenBank) which can help confirm results from the initial GenBank BLAST search. The RefSeq BLAST search cannot substitute for the GenBank BLAST search because RefSeq does not contain known miRNA or other known small non-coding RNA entries.

- 10. When analyzing sequences, give the most attention to the hits with short sequence homology (usually 18-35 nt) to mRNA or 3'UTR of mRNA in plus/minus orientation to mRNA sequences. These are potentially new microRNA-like sequences.
- 11. An important criterion for miRNA validation is evidence of miRNA biogenesis. This typically requires the identification of pre-miRNA stem loop precursors. For secondary structure analysis, use the whole insert sequence as derived in step 9, as well as the complementary strand. For this purpose, we utilized the Sfold tool which is available online at http://sfold.wadsworth.org (12). Folding analysis was performed on both the direct sequence read from the clone and the complementary sequence, from which we select the best stem-loop structure with lowest minimum free energy.
- 12. Complete bioinformatics analysis of the data gathered in step 10 together with predicted secondary structure from step 11 can reduce the number of potential new microRNA or microRNA-like sequences that require further experimental analysis. Based on the definition of biogenesis of miRNA sequences, the mature miRNA should be in a stem of the stem-loop structure and lie on one side of the stem.
- 13. Northern blotting is still the most important criterion to categorize a new sequence as a miRNA.

Note: We recommend that the oligonucleotide probes used for Northern blot hybridization are designed to be complementary to the mRNA sequence or 3'-UTR sequence of mRNA (this is with the assumption that this particular mRNA is the target for new miRNA). In the case of a lack of signal in the expected region, you can try to use the sequence homologous to the mRNA sequence (in the case that the mRNA is the precursor in miRNA maturation and the target is a different mRNA sequence which is not found in the BLAST search).

Note: Lack of signal in the expected range may be due to low abundance level of the particular putative miRNA in total RNA and the low sensitivity of Northern blot hybridization.

14. RT-PCR can be used to reduce the number of sequences subjected to Northern blotting. RT-PCR is a much faster and more sensitive

method than Northern blot analysis. Since the miRNA and miRNAlike molecules are very small, a modified form of RT-PCR termed 3' RACE RT-PCR can be performed. Both Northern blotting and RT-PCR analyses are based on the specific hybridization of a small synthetic oligonucleotide to the target RNA, either as a probe or as a primer. Northern blot analysis can estimate the size of the miRNA directly, while RT-PCR can also be used to estimate the size of the miRNA by gel electrophoresis. In this case the size is estimated by subtraction of the length of the adaptor from the size of the RT-PCR products. Furthermore, both methods can identify precursor forms of miRNA. The method of Shi and Chiang (11) can be adapted for RT-PCR analysis of putative miRNAs. In this method, a poly-A tail is added to the 3'-end of the RNA with poly-A polymerase (see Figure 7). An oligo-dT containing adaptor is annealed and used for first strand cDNA synthesis. Following reverse transcription, a primer complimentary to the adaptor was used as a reverse RT-PCR primer. The forward primer consisted of the miRNA-like sequence itself. We recommend using 0.5 μ g of the total RNA as starting material. For tailing of total RNA, use poly-A polymerase (we recommend Epicentre's A-Plus™ Poly(A) Polymerase Tailing Kit, Cat. # PAP5104H) and follow the manufacturer's protocol.

15. To analyze the presence of putative miRNA sequences in total RNA, prepare a PCR master mix for number of reactions equal to the number of different sequences to be analyzed. For PCR, we recommend KlenTaq LA DNA Polymerase from Sigma (Cat. # D5062).

	<u>1 Rx</u>	<u>n</u>	<u>10 Rxn</u>		
RNase-free Water	15.3	μl	153	μl	
10X PCR Buffer	2.0	μl	20	μl	
50X dNTP Mix (10 μM each)	0.4	μl	4	μl	
Forward RT-PCR Primer	0.4	μl	4	μl	
Reverse RT-PCR Primer	0.4	μl	4	μl	
cDNA from step 14	1.0	μl	10	μl	
PCR Polymerase	0.5	μl	5	μl	
Total volume	20.0	μl	200	μl	

- 16. Place the reactions in a thermal cycler, and cycle using the following program:
 - 95°C for 2 min
 - 95°C for 20 sec 25 cycles
 - 60°C for 25 sec _
 - 15°C hold
- 17. After amplification, analyze 2.5 μl of each reaction on a 3.0-3.5% agarose gel in 1X TBE or TAE Buffer. Include a DNA size ladder with

markers in the range of 50-2,000 bp (*e.g.*, Bio-Rad AmpliSizeTM DNA Ladder).

18. If you confirm by Northern blot or by 3' RACE RT-PCR analysis that the sequence is very likely to be a new miRNA or miRNA-like molecule, you may want to examine the distribution and maturation stages of this RNA sequence in different tissues or different cell lines with different treatments (inducing/repressing conditions). For this purpose, it is very convenient to use 3' RACE RT-PCR. For example, see Figures 7 and 8. In many cases, miRNAs display different patterns in different tissues which can be an additional indication of discovery of new non-coding small RNA molecules.

G. Size Selection of Amplified cDNA (optional)

 Amplified cDNA from Step D.2 can be size selected for low molecular weight products. For purification, use 5 µl of cDNA solution. Apply the sample on a 3-3.5% agarose gel with 1X TAE. Include a DNA size ladder with markers in the range of 50-2,000 bp (e.g., Bio-Rad AmpliSize™ DNA Ladder). Cut the gel between 50 to 120 bp (even if you do not see any smear in this region). Purify cDNA from the agarose using QIAGEN's QIAquick Gel Extraction Kit (Cat. # 28704), following the manufacturer's protocol. Use all of the extracted material for additional PCR amplification. Add the following:

53 μl	RNase-free Water
10 μl	10X PCR Buffer
2 μl	dNTP Mix
2 µl	RT and PCR Primer
3 μΙ	PCR Polymerase (50X)
100 μl	Total volume (including the 30 μ l from gel-
	purified material)

- 2. Place the reactions in a thermal cycler, and cycle using the following program:
 - 95°C for 2 min
 - 95°C for 20 sec 25 cycles
 - 68°C for 25 sec
 - 15°C hold
- After amplification, run 2.5 µl of each reaction on a 3.0-3.5% agarose gel in 1X TBE or TAE Buffer. Include a DNA size ladder with markers in the range of 50-2,000 bp (e.g., Bio-Rad AmpliSize[™] DNA Ladder). You should see results similar to those shown in Figure 4. The typical yield is 2-3 µg cDNA. You can continue adding two-cycle

increments until you see the sufficient product from your amplification reaction, however, you should not exceed 30 cycles.



Fig. 4. Distribution of cDNA after amplification before and after size selection.

You can continue adding two-cycle increments until you see the sufficient product from your amplification reaction. However, you should not exceed 30 cycles.

H. Gene-Specific Amplification Using Amplified cDNA

The amplified cDNA is ready to use as a template without purification. However, you must denature the amplified cDNA by incubating it for 10 minutes at 95°C before starting gene-specific PCR. It is critical that you use a non-hotstart PCR polymerase. We typically use Ambion's SuperTaq Polymerase (Cat. # AM2052). We recommend that the amplified cDNA be added as a 1% component of your gene-specific PCR reactions. Thus, for a 25 μ I gene-specific PCR reaction, you should add 0.25 μ I of the amplified cDNA; for a 50 μ I PCR reaction, add 0.5 μ I of the amplified cDNA, etc.

As small RNA controls, we recommend using Ambion's RT-PCR primer pairs for 5S rRNA and U6 small RNA.

III. Troubleshooting

A. No Product from cDNA Amplification

If, after step D.3, you do not see a smear on the 3.0-3.5% gel for your RNA samples, try the following suggestions:

If you do not see a smear for any samples, including the Control RNA...

• One or more of the reagents were omitted during the procedure or the volume of the reactions is incorrect. Calibrate your pipette and try amplifying the Control RNA again.

If you see a smear for the Control RNA, but not for your RNA samples...

- You may have less starting RNA than measured. Place the amplification reactions back in the thermocycler for an additional three cycles. If the expected smear described in Section D.3 is generated, you should continue with qRT-PCR.
- If, after additional cycles, there is still no smear or a very weak smear compared with the Control RNA reaction, your RNA may either be (1) too degraded or (2) contain an inhibitor. Try the amplification again after repurifying the RNA. If you still do not get sufficient yield, try a different RNA purification kit.

B. No Product with Gene-Specific Primers

- If you have confirmed that the amplification in step D.3 was successful, but you do not get a product or get a non-specific product with your gene specific primers, there may be a problem with your PCR reagents. Try to amplify with primers specific for an abundant gene such as mi16 or mi24, which are ubiquitously expressed miRNA. If the PCR still fails to generate a product after 35 cycles, try using new PCR reagents and enzyme.
- Try using Clontech's QTaq Polymerase (Cat. # 639651).

C. No Colonies after TOPO TA cloning

- Try to use fresh PCR reaction product to make sure the TOPO TA cloning kit is working.
- Submit amplified cDNA for an additional 5 PCR cycles and repeat cloning.

D. No Product with PCR primer during colony screening

 If you do not amplify product, or see non-specific products (smearing) with PCR primers during colony screening, there may be a problem with your PCR reagents. Try to amplify with M13 forward and reverse primers. If the PCR still fails to generate a product after 35 cycles, try using new PCR reagents and enzyme.

• We typically use KlenTaq LA DNA Polymerase from Sigma (Cat. # D5062).

IV. References

- 1. **Sonthelmer, E. J., Carthew, R. W.** 2005. Silence from within: Endogenous siRNAs and miRNAs. Cell *122*:9-12.
- 2. Zamore, P.D., Haley, B. 2005. Ribo-gnome: The big world of small RNAs. Science *309*: 1519-1524.
- 3. Bartel, D. 2004. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell *116*: 281-297.
- 4. Kim, Narry V. 2005.Small RNAs: Classification, Biogenesis, and Function. Mol. Cells. 19:1-15.
- Valencia-Sanchez, MA., Liu, J., Hannon, GJ., Parker, R., 2006. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-525.
- Lewis B.P, Burge C.B, Bartel, D.P. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
- Xie X., Lu J., Kulbokas, E.J., Goulub, T.R., Mooth, V., Lindblad-Toh, K., Lander, E.S. and Kellis, M. Systematic discovery of regulatotory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature.434:338-45.
- Lagos-Quintana, M., Rauhut, R., Lendeckel, W., Tuschl, T. 2001. Identification of Novel Coding for Small Expresses RNAs. Science 294: 853-858.
- Basyuk, E., Suavet, F., Doglio, A., Bordonne, R., Bertrand, E. 2003. Human let-7 stem-loop precursors harbor features of RNase III cleavage products. Nucleic Acids Res 31: 6593-6597.
- 10. **Chomczynski P., and Mackey, K**. One-hour downward capillary blotting of RNA at neutral pH. 1994, Anal. Biochem. 221, 303-305.
- 11. **Shi, R., Chiang, V.L.**, 2005. Facile means for quantifying microRNA expression by real-time PCR. BioTechniques. 39:519-525.
- 12. Ding, Y., Chan, C.Y., and Lawrence, C.E. (2005) RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. RNA 11, 1157-1166.
- Griffiths-Jones,S., Grocock, R.J., Van Dongen, S., Bateman, A., Enright, A.J. 2006. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Research 34: D140-D144.
- Shingara, J., Keiger, K., Shelton, J., Laosinchai-Wolf, W., Powers, P., Conrad, R., Brown, D., Labourier, E. 2005. An optimized isolation and lebeling platgorm for accurate microRNA expression profiling. RNA *11*:1461-1470.
- He, L., Thomson, J.M., Hemann, M.T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S.W., Hannon, G.J., Hammond, S.M. 2005. A microRNA polycistron as a potential human oncogene. Nature 435: 828-833.
- 16. Lai, E.C., Wiel, C., Rubin, G.M. 2004. Complementary miRNA pairs suggest a regulatory role for miRNA:miRNA duplexes. RNA *10*:171-175.

- Ambros, V., Bartel, B., Bartel, D.P., Burge, C.B., Carrington, J.C., Chen, X., Dreyfuss, G., Eddy, S.R., Griffiths-Jones, S., Marshall, M., Matzke, M., Ruvkun, G., Tuschl, T. 2003. A uniform system for microRNA annotation. RNA 9:277-279.
- 18. **Obernosterer, G., Leuschner, P.J.F., Alenius, M., Martinez, J.** 2006. Posttranscriptional regulation of microRNA expression. RNA *12*:1-7.
- Dostie, J., Mourelatos, Z., Yang, M., Sharma, A., Dreyfuss, G. 2003. Numerous microRNPs in neuronal cells containing novel microRNAs. RNA 9: 180-186.

V. Appendix

A. Data Generated with the MicroRNA Discovery[™] Kit

The data below demonstrate that the cloning and amplification techniques used in SBI's MicroRNA Discovery[™] Kit enrich for the majority of known miRNAs. Additionally, data is presented that demonstrates the power of the technique to identify novel RNase III processed miRNA-like transcripts.

A robust miRNA amplification procedure should both maintain the presence of individual miRNAs within the population, and enrich specifically for the target miRNA molecules. In our experiment, we have demonstrated that the majority of known miRNAs (13 of 14) were amplified and maintained throughout the amplification procedure.

It should be expected that our amplification process will enrich for miRNA-like sequences. We examined this question by comparing the number of PCR cycles needed to amplify a miRNA and the number needed to amplify a segment of the 5S rRNA transcript. Before amplification, the difference in the number of cycles needed to amplify the 5S rRNA and miR-16 was +9. After amplification the number of cycles was -1. The difference was about 10 cycles, which suggests an enrichment factor of about 1,000. Care was taken to avoid the plateau phase of the PCR amplification by limiting cycle numbers. Results are shown in Table 2.

	Cycles 5S rRNA	of PCR VmiR-16	Difference in cycles (miR-16 - 5S rRNA)		
Before amplification	23	32	+9		
After amplification	23	22	-1		

 Table 2. Estimation of miR-16 enrichment factor after cDNA amplification.

Using techniques described in detail in the MicroRNA Discovery[™] Kit, we amplified and cloned the RNase III processed RNA fraction from total RNA without any size selection. The size of the cloned cDNA inserts ranged in size between about 100 and 300 bp. In the first small survey, 60 clones were selected for further examination by sequencing. BLAST searches against GenBank found that approximately 60% clones were derived from rRNAs or tRNAs and were omitted from further study. The remaining clones were found to have homologies of between 18-29 nts to sequences in GenBank. While not 100% predictive, it is expected that a true miRNA will have a detectable level of similarity with its corresponding target transcript. miRNAs regulate

mRNA translation and/or mRNA stability through hybridization with their target mRNA transcripts. Ultimately the set of non-rRNA/tRNA clones were found to contain four previously known microRNAs, and seven new miRNA-like sequences which are discussed in more detail below.

Four cDNA clones (4, 7, 10, and 13) were identified to contain miRNA-like sequences. Clones 10 and 13 each contained more than one miRNA-like sequence, for a total of seven individual miRNA-like sequences (4, 7, 10a, 10b, 13a, 13b, 13c). Multiple miRNAs in the same precursor, referred to as polycistronic miRNAs, have been described (15). With current miRNA cloning methods, these longer precursor molecules are lost during the multiple size selection steps.

	cDNA clone	MicroRu	Length of L	Northern (Inc.)	Size of the P.	uuct minus adaptor (bp)
known	miR-1	6	22	~22	~20	
	4	4	22	~37 ~90 pre*	~35	
	7	7	18	~24 ∼75 and ∼140 pre*	~20	
	10	10a	18	-	~20	
unknown		10b	28	-	~35	
	13	13a	18	-	~20	
		13b	29	-	~35	
		13c	22	-	~20	
			*	pre: pre	cursor?	-

 Table 3.
 Summary of miRNA-like sequences identified.

According to the recommended criteria for miRNA annotation (17), a sequence must fulfill several requirements to be annotated as a miRNA. The first is verification of expression by Northern blots or cDNA cloning of a small RNA ~22 nts. Figure 6 shows results of Northern blot hybridization for clones 4 and 7, where they demonstrate transcripts of distinctly different sizes.



Fig. 6. Northern blot analysis of miRNA-like sequences. Synthetic oligonucleotides representing the miRNA-like complimentary sequences in GenBank were used as hybridization probes. 10 nt size markers are indicated. **A.** Results of hybridization of the probe complementary to sequence from clone 4. **B.** Results of hybridization of the probe complementary to sequence from cDNA clone 7.

For the five remaining sequences (10a, 10b, 13a, 13b, and 13c) we did not detect any signal on Northern blot which may be due to low abundance level for these molecules in the total RNA.

3'-RACE RT-PCR was also performed to identify the presence and size of all seven putative miRNA transcripts. A poly-A tail is added to the 3'end of the RNA with poly-A polymerase. An oligo-dT containing adaptor is annealed and used for first strand cDNA synthesis. Following reverse transcription, a primer complimentary to the adaptor was used as a reverse RT-PCR primer. The forward primer consisted of the miRNA-like sequence itself (see Figure 7).



Fig. 7. Schematic of 3' RACE RT-PCR method.



Fig. 8. 3' RACE RT-PCR for seven newly identified miRNA-like sequences and miR-16. Numbers on the top of the gel correspond to cDNA clone number. Letters indicate specific sequence found in corresponding clone.

A second criterion for miRNA annotation is evidence of miRNA biogenesis. This typically requires the identification of pre-miRNA stem loop precursors. Stem loops were observed in majority of cDNA clones (data not shown).

For more information and additional data, please visit our website at <u>www.systembio.com</u>.

B. Related Products

 Pre-Made MicroRNA-Enriched cDNAs (Cat. # RA500A-1 – RA509A-1)

Tissue-specific amplified cDNA generated by SBI using the MicroRNA Discovery™ Kit can be used for cloning microRNA.

- Global MicroRNA Amplification Kit (Cat. # RA400A-1) Simple amplification kit allows cDNA amplification for qRT-PCR and microarray studies from as little as 50 ng of starting total RNA.
- Full Spectrum[™] Complete Transcriptome RNA Amplification Kit (Cat. # RA101A-1) The Full Spectrum RNA Amplification Kit provides an inexpensive

method to amplify reverse transcribed RNA in a sequence independent, unbiased, and uniform manner with better representation of 5' end of mRNA sequences. This approach maintains the relative levels of each transcript in the starting mRNA samples—even when using starting amounts of RNA as low as 5ng or when using heavily degraded RNA.

• Full Spectrum[™] MultiStart Primers for T7 IVT (Cat. # RA300A-2) Extract more data from your RNA than currently available primers in nearly all commercially-available T7 IVT kits using Full Spectrum[™] technology. Just replace the existing T7 primer with the Full Spectrum[™] primers. Compatible with Affymetrix GeneChip[®] hybridization.

C. Technical Support

For more information about SBI products and to download manuals in PDF format, please visit our web site:

http://www.systembio.com

For additional information or technical assistance, please call or email us at:

System Biosciences (SBI) 1616 North Shoreline Blvd. Mountain View, CA 94043

Phone: (650) 968-2200 (888) 266-5066 (Toll Free)

Fax: (650) 968-2277

E-mail:

 General Information:
 info@systembio.com

 Technical Support:
 tech@systembio.com

 Ordering Information:
 orders@systembio.com

VI. Licensing and Warranty Statement

Limited Use License

Use of the MicroRNA Discovery[™] Kit (*i.e.*, the "Product") is subject to the following terms and conditions. If the terms and conditions are not acceptable, return all components of the Product to System Biosciences (SBI) within 7 calendar days. Purchase and use of any part of the Product constitutes acceptance of the above terms.

Purchase of the product does not grant any rights or license for use other than those explicitly listed in this Licensing and Warranty Statement. Use of the Product for any use other than described expressly herein may be covered by patents or subject to rights other than those mentioned. SBI disclaims any and all responsibility for injury or damage which may be caused by the failure of the buyer or any other person to use the Product in accordance with the terms and conditions outlined herein.

SBI has pending patent applications related to the Product. For information concerning licenses for commercial use, contact SBI.

Limited Warranty

SBI warrants that the Product meets the specifications described in the accompanying Product Analysis Certificate. If it is proven to the satisfaction of SBI that the Product fails to meet these specifications, SBI will replace the Product or provide the purchaser with a refund. This limited warranty shall not extend to anyone other than the original purchaser of the Product. Notice of nonconforming products must be made to SBI within 30 days of receipt of the Product.

SBI's liability is expressly limited to replacement of Product or a refund limited to the actual purchase price. SBI's liability does not extend to any damages arising from use or improper use of the Product, or losses associated with the use of additional materials or reagents. This limited warranty is the sole and exclusive warranty. SBI does not provide any other warranties of any kind, expressed or implied, including the merchantability or fitness of the Product for a particular purpose.

SBI is committed to providing our customers with high-quality products. If you should have any questions or concerns about any SBI products, please contact us at (888) 266-5066.

© 2006 System Biosciences (SBI).